A new study led by researchers at Hospital for Special Surgery (HSS) suggests that currently available therapies may help control chronic muscle inflammation in Duchenne muscular dystrophy (DMD), a severe condition that leads to muscle weakness and premature death.
To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec, the American Academy of Neurology (AAN) has issued an Evidence in Focus article, published May 14, 2025, online in Neurology.
Most dental offices are independent practices and often don't have access to a patient's medical history. For providing dental care, it is critical that dentists have up-to-date medical and medication histories of their patients to reduce risk during procedures and ensure the success of the treatment.
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of
our websites
and requested to be notified of additional information.
